Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Camrelizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as an immune checkpoint inhibitor. By blocking the interaction between PD-1 on T cells and its ligand PD-L1 on tumor cells, camrelizumab prevents immune evasion by cancer cells and enhances antitumor immune responses[1][4][6][8]. When combined with chemotherapy, this regimen has demonstrated improved efficacy compared to chemotherapy alone in several solid tumors, including non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma[2][5]. Camrelizumab was developed in China and has been studied in multiple advanced cancers. The combination with chemotherapy is used as a first-line or neoadjuvant treatment for certain locally advanced or metastatic cancers.
- Brand names
- AiRuiKa + chemotherapy
- Other names
- anti-PD-1 antibody + chemotherapycamrelizumab plus chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)GART (GAR transformylase)TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)DNA
Beyond the preview
Go deeper on camrelizumab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + chemotherapy.